ea0092ps3-29-08 | Treatment 2 | ETA2023
Lahner Harald
, Maria Machlah Yara
, Blumenstein Laura
, Theurer Sarah
, Weber Manuel
, Weber Frank
, Dralle Henning
, Fuhrer Dagmar
, Brandenburg Tim
Therapeutic strategy for the management of radioiodine-refractory differentiated thyroid cancer (rrDTC) and advanced medullary thyroid cancer (MTC) had changed with the introduction of the multityrosine-kinase-inhibitors (MKI) sorafenib&lenvatinib and vandetanib&cabozantinib respectively. Only recently, the market approval of pralsetinib (FDA) and selpercatinib (FDA and EMA) as first highly selective RET(rearranged during transfection)- inhibitors have expande...